Who is sponsoring NCT05834296?

NCT05834296 is sponsored by Alzamend Neuro, Inc..

What drugs are being tested in NCT05834296?

Interventions in NCT05834296: ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo.

What condition does NCT05834296 study?

NCT05834296 studies Alzheimer Disease.

Is NCT05834296 still recruiting?

NCT05834296 is currently active, enrolled. Last updated 2 September 2025.

Last reviewed 2025-09-02 · How we verify

NCT05834296

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Active, enrolled Phase 1, PHASE2 Last updated 2 September 2025

What this trial tests

Phase 1, PHASE2 trial testing ALZN002 (autologous DCs pulsed with E22W mutant peptide). in Alzheimer Disease in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 July 2023

Primary endpoint
3 March 2028

3 March 2028

Quick facts

Lead sponsor	Alzamend Neuro, Inc.
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	30
Start date	5 July 2023
Primary completion	3 March 2028
Estimated completion	3 March 2028
Sites	1 location across United States

Drugs / interventions tested

ALZN002 (autologous DCs pulsed with E22W mutant peptide). — full drug profile →
Placebo

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Alzamend Neuro, Inc. — full company profile →

Who can join

Adults 60 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2024.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2024 · cited 209× · PMID 38659717 · DOI 10.1002/trc2.12465
Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease.
Thawabteh AM, Ghanem AW, AbuMadi S, Thaher D, et al · · 2024 · cited 26× · PMID 39519769 · DOI 10.3390/molecules29215131
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis.
Almeida ZL, Vaz DC, Brito RMM. · · 2025 · cited 19× · PMID 39446217 · DOI 10.1007/s12035-024-04543-4
Targeting Amyloid-β Proteins as Potential Alzheimer's Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health.
Abduljawad AA, Alkinani KB, Zaakan A, AlGhamdi AS, et al · · 2025 · cited 1× · PMID 41304975 · DOI 10.3390/ph18111731
Decoding immunometabolism with next-generation tools: lessons from dendritic cells and T cells.
Wang YH, Wang L, Ho PC. · · 2025 · cited 1× · PMID 40957982 · DOI 10.1038/s44318-025-00569-z

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Alzamend Neuro, Inc. trials

Trials by the same sponsor.

NCT05363293 — Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05834296 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alzamend Neuro, Inc.
Last refreshed: 2 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05834296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing